BT
BTMD.O
—
NASDAQ
Diversified Professional Information Services
Biote Corp
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
90,0M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
18,5 %
ROE
-46,2 %
Net margin
14,1 %
Debt / equity
-2,14
Beta
—
52w range
—
Volume
122
Day range
$1,90–$2,00
Prev close
$1,92
Open
$1,90
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Biote Corp provides industrial services, primarily focused on the pharmaceuticals sector, generating revenue through service contracts and operational income.
Business. Biote Corp (BTMD.O) is a professional information services company operating within the Industrial & Commercial Services sector. The firm generates revenue primarily through a subscription model, focusing on industrial services activities. Biote Corp is headquartered in the United States and is listed on the NASDAQ stock exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available in the provided data.
Classification99 %
SectorIndustrials
Industry groupDiversified Professional Information Services
Generated · model-assisted
Sell-side consensus
BUY5 analysts
4 buy1 hold0 sell
Avg 12m price target2,97
Analyst recommendations
5 analysts · consensus BuyBuy4
Hold1
Sell0
12-month price target
2,97
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
5 analysts · indicative
Ownership→
BlackRock Institutional Trust Company, N.A.
largest disclosed fund holder
Profitability→
-46,2 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials · THIS SECTOR−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to BTMD.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Biote Corp (BTMD.O) is a professional information services company operating within the Industrial & Commercial Services sector. The firm generates revenue primarily through a subscription model, focusing on industrial services activities. Biote Corp is headquartered in the United States and is listed on the NASDAQ stock exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available in the provided data.
Classification99 %
SectorIndustrials
Industry groupDiversified Professional Information Services
AI synthesis
GENERATEDBiote Corp's capital structure is characterized by a negative total equity of $58.54 million and a debt-to-equity ratio of -2.14, indicating a leveraged position with liabilities exceeding assets. The company's liquidity is assessed as medium, with a current ratio of 1.22, suggesting it can cover short-term obligations but with limited buffer. Free cash flow of $28.33 million supports operational flexibility, though the negative net cash position raises concerns about long-term solvency.
Profitability metrics show a return on assets (ROA) of 25.13%, which is strong relative to the industry median of 18.5% for Professional Information Services. However, the return on equity (ROE) is negative at -46.2%, reflecting the company's negative equity position and high leverage. Operating income of $35.55 million and a gross margin of 71.45% indicate efficient operations, but the net income of $27.05 million is constrained by interest and debt servicing costs.
Geographically, Biote Corp's revenue is concentrated in the pharmaceuticals sector, as per its sector classification classification, with no disclosed geographic diversification in the latest financials. This concentration increases exposure to sector-specific risks, including regulatory changes and market volatility.
The company's growth trajectory is mixed. Revenue of $192.22 million in the latest period shows a 12.3% year-over-year increase, but the outlook for the current fiscal year (FY) is for a 5.1% decline in revenue, with a further 3.8% contraction expected in the next FY. This suggests a slowdown in demand or pricing pressures in the pharmaceuticals sector.
Risk factors include a high debt load, with long-term debt of $125.53 million, and a negative net cash position. The risk assessment indicates a low dilution potential, with no significant changes in shares outstanding between basic and diluted shares. However, the company's negative equity and high leverage increase credit risk and may limit access to additional financing.
Recent events include a price target range from $2.00 to $4.00, with a mean of $2.97 and a median of $3.00, reflecting analyst optimism despite the company's financial challenges. The mean recommendation of 2.00 (on a 1-5 scale) suggests a generally positive outlook, with three "buy" ratings and one "hold".
Key takeaways
- Biote Corp has a strong ROA of 25.13% but a negative ROE of -46.2% due to high leverage.
- The company's liquidity is medium, with a current ratio of 1.22 and free cash flow of $28.33 million.
- Revenue growth has slowed, with a 12.3% YoY increase followed by a projected 5.1% decline in the current FY.
- Analysts are cautiously optimistic, with a mean price target of $2.97 and a "buy" recommendation.
- The company's debt load and negative equity position pose credit and solvency risks.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$2,29
Market cap
$76.6M
Enterprise valueⓘ
$202.2M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
5.7x
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
-$58.5M
Net cashⓘ
-$125.5M
Current ratioⓘ
1.2
Debt / equityⓘ
-2.1
ROAⓘ
25.1%
ROEⓘ
-46.2%
Cash conversionⓘ
130.0%
CapEx / revenueⓘ
-3.6%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
Peer comparison8 peers · vs BTMD · multiples and returns
SP
SPGI—
SPGI.K
$416,63
124,0B USDP/E
28,9x
+26,1 vs self
Div yield
0,9 %
— vs self
ROE
14,3 %
+60,5 vs self
MC
MCO—
Moody'S Corp
$483,36
85,7B USDP/E
37,4x
+34,6 vs self
Div yield
0,7 %
— vs self
ROE
82,1 %
+128,3 vs self
TR
TRI—
TRI.TO
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BR
BR—
Broadridge Financial Solutio
$157,34
18,4B USDP/E
14,9x
+12,1 vs self
Div yield
2,4 %
— vs self
ROE
41,4 %
+87,7 vs self
EF
EFX—
Equifax Inc
$174,11
21,0B USDP/E
32,2x
+29,4 vs self
Div yield
1,1 %
— vs self
ROE
14,5 %
+60,7 vs self
TR
TRU—
Transunion
$79,98
15,4B USDP/E
27,6x
+24,7 vs self
Div yield
0,7 %
— vs self
ROE
10,3 %
+56,5 vs self
MS
MSCI—
MSCI INC.
$574,43
42,2B USDP/E
37,2x
+34,4 vs self
Div yield
1,2 %
— vs self
ROE
-43,3 %
+2,9 vs self
MO
MORN—
MORNINGSTAR, INC.
$198,93
7,6B USDP/E
18,0x
+15,2 vs self
Div yield
1,2 %
— vs self
ROE
30,6 %
+76,8 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
0,29
Predicted surprise
+0,00
Beat probability
45 %
Analysts
5
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-16 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,29 |
| Revenue | —no estimate | —no estimate | 191,7M USD |
| Operating income | —no estimate | —no estimate | 25,6M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution5 analysts
Strong buy1
Buy3
Hold1
Sell0
Strong sell0
12-month price target$2,97 · Median $3,00
Low $2,00High $4,00
Operating income · consensus25,6M USD
EPS surprise
+155,2 %
reported vs consensus · beat
Revenue surprise
+0,3 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$2,00
Mean$2,97
Median$3,00
High$4,00
Spot$2,29
+29.9 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskMedium
Filing-based flags
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Op Margin18,5 %Above median
Net Margin14,1 %Above median
ROE-46,2 %Bottom quartile
Capex / Rev-3,6 %Below median
D/E-2,14Best in class
Cash Conv1,30Below median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 2 047 123 sh1 exercises · 16 grants9 insiders
- Director, Interim CEO · Stock Options (Right to buy) → Class A Common StockAcquired 206 746 @ $2,46grant · 2026-06-12
- Director, Executive Chairman · Employee Stock Option (Right to Buy) → Class A Common StockAcquired 114 157 @ $2,34grant · 2026-06-08
- Director · Stock Option (Right to Buy) → Class A Common StockAcquired 130 000 @ $2,34grant · 2026-06-08
- Director · Stock Option (Right to Buy) → Class A Common StockAcquired 130 000 @ $2,20grant · 2026-05-12
- Director · Deferred Settlement RSU → Class A Common StockAcquired 35 259grant · 2026-05-12
- Director · Deferred Settlement RSU → Class A Common StockAcquired 37 777grant · 2026-05-12
- Director · Deferred Settlement RSU → Class A Common StockDisposed 21 407exercise · 2026-05-12
- Director · Deferred Settlement RSU → Class A Common StockAcquired 39 036grant · 2026-05-12
- Director · Stock Option (Right to Buy) → Class A Common StockAcquired 130 000 @ $2,20grant · 2026-05-12
- Director · Deferred Settlement RSU → Class A Common StockAcquired 31 481grant · 2026-05-12
- Director · Stock Option (Right to Buy) → Class A Common StockAcquired 130 000 @ $2,20grant · 2026-05-12
- Director · Stock Option (Right to Buy) → Class A Common StockAcquired 130 000 @ $2,20grant · 2026-05-12
- Director · Stock Option (Right to Buy) → Class A Common StockAcquired 195 000 @ $2,20grant · 2026-05-12
- Director, 10% owner · Stock Option (Right to Buy) → Class A Common StockAcquired 121 452 @ $2,20grant · 2026-05-12
- General Counsel · Employee Stock Option (Right to Buy) → Class A Common StockAcquired 88 800 @ $2,19grant · 2026-05-01
- Chief Financial Officer · Employee Stock Option (Right to Buy) → Class A Common StockAcquired 107 169 @ $1,43grant · 2026-04-01
- Director, Chief Executive Officer · Employee Stock Option (Right to Buy) → Class A Common StockAcquired 441 653 @ $1,43grant · 2026-04-01
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
Source documents
- Biote Corp Market data — financials · 2026-05-27
- Biote Corp Market data — analyst estimates · 2026-05-27
- Biote Corp Market data — ESG · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2024-06-300,00 %$12M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2024-12-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Funds · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Mixed / flat0 buys · 0 sellsnet $01 insiders · last 365d
- Director · Class A Common StockOther 21 407 · 2026-05-12
Short positioning
578.7Kshares short+4.5% vs prior
2.82days to cover
34.9%short of daily vol
1.8Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
BTMD.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskMedium
Net cash is negative after subtracting total debt.
Evidence & claims
From filings & derived data- Capex (YoY) (2025-12-31 vs 2024-12-31): -22.0%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -12.1%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 756.7%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 12.5%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -38.7%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 44.7%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -29.6%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -5.7%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 855.6%Derived (calculated)
- Net margin (FY 2025-12-31): 14.1%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -2.5%Derived (calculated)
- Return on equity (FY 2025-12-31): -46.2%Derived (calculated)
- Return on assets (FY 2025-12-31): 25.1%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): -2.70xDerived (calculated)
- Current ratio (FY 2025-12-31): 1.22xDerived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 722.2%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -22.2%Derived (calculated)
- Pre-tax income (annual): USD 37.58MSEC XBRL filing
- Revenue (annual): USD 192.22MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES 1SEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES 1SEC XBRL filing
- Total liabilities (annual): USD 158.01MSEC XBRL filing
- Long-term debt (annual): USD 103.12MSEC XBRL filing
- Cash & equivalents (annual): USD 24.12MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-12 00:00 UTCINSIDER3 insider transactions — 2026-06 3 derivative
2026-06-12INSIDERPeterson Robert Charles acquired 206.7k sh Stock Options (Right to buy) — Director, Interim CEO
2026-06-08INSIDERBeer Marc D acquired 114.2k sh Employee Stock Option (Right to Buy) — Director, Executive Chairman
2026-06-08INSIDERChristensen Bret acquired 130.0k sh Stock Option (Right to Buy) — Director
2026-05-12 00:00 UTCINSIDER13 insider transactions — 2026-05 12 derivative
2026-05-12INSIDERMORRIS DEBRA L transacted 21.4k sh Class A Common Stock — Director
2026-05-12INSIDERHEYER ANDREW R acquired 35.3k sh Deferred Settlement RSU — Director
2026-05-12INSIDERHEYER ANDREW R acquired 130.0k sh Stock Option (Right to Buy) — Director
2026-05-12INSIDERJacoby Dana Lynn acquired 130.0k sh Stock Option (Right to Buy) — Director
2026-05-12INSIDERBarrera Richard R acquired 121.5k sh Stock Option (Right to Buy) — Director, 10% owner
2026-05-12INSIDERMORRIS DEBRA L disposed of 21.4k sh Deferred Settlement RSU — Director
2026-05-12INSIDERMORRIS DEBRA L acquired 39.0k sh Deferred Settlement RSU — Director
2026-05-12INSIDERMORRIS DEBRA L acquired 130.0k sh Stock Option (Right to Buy) — Director
2026-05-12INSIDERCone Stephen Mark acquired 31.5k sh Deferred Settlement RSU — Director
2026-05-12INSIDERCone Stephen Mark acquired 130.0k sh Stock Option (Right to Buy) — Director
2026-05-12INSIDERJacoby Dana Lynn acquired 37.8k sh Deferred Settlement RSU — Director
2026-05-12INSIDERBeer Marc D acquired 195.0k sh Stock Option (Right to Buy) — Director
2026-05-01INSIDERMonico Daniel Michael acquired 88.8k sh Employee Stock Option (Right to Buy) — General Counsel
2026-04-01 00:00 UTCINSIDER2 insider transactions — 2026-04 2 derivative
2026-04-01INSIDERPeterson Robert Charles acquired 107.2k sh Employee Stock Option (Right to Buy) — Chief Financial Officer
2026-04-01INSIDERChristensen Bret acquired 441.7k sh Employee Stock Option (Right to Buy) — Director, Chief Executive Officer
2025-06-09 00:00 UTCINSIDER1 insider transaction — 2025-06 1 derivative
2025-05-13 00:00 UTCINSIDER15 insider transactions — 2025-05 · net buy $1.5M 11 derivative
2025-04-30 00:00 UTCINSIDER9 insider transactions — 2025-04 · net buy $454k
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage